Top 10 Papers voted by ESC for 2023 in Cardio Metabolic

Top 10 Papers voted by ESC for 2023 in Cardio Metabolic

Bariatric surgery and cardiovascular disease a systematic review and meta-analysis

22 February 2024
Read more: Bariatric surgery and cardiovascular disease a systematic review and meta-analysis
Top 10 Papers voted by ESC for 2023 in Cardio Metabolic

Bone marrow activation in response to metabolic syndrome and early atherosclerosis

22 February 2024
Read more: Bone marrow activation in response to metabolic syndrome and early atherosclerosis
Top 10 Papers voted by ESC for 2023 in Cardio Metabolic

Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes

22 February 2024
Read more: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
Top 10 Papers voted by ESC for 2023 in Cardio Metabolic

Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER

22 February 2024
Read more: Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER
Top 10 Papers voted by ESC for 2023 in Cardio Metabolic

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

22 February 2024
Read more: Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Top 10 Papers voted by ESC for 2023 in Cardio Metabolic

Effects of aspirin on dementia and cognitive function in diabetic patients the ASCEND trial

22 February 2024
Read more: Effects of aspirin on dementia and cognitive function in diabetic patients the ASCEND trial
Top 10 Papers voted by ESC for 2023 in Cardio Metabolic

Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled

22 February 2024
Read more: Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled
Top 10 Papers voted by ESC for 2023 in Cardio Metabolic

Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies

22 February 2024
Read more: Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies
Top 10 Papers voted by ESC for 2023 in Cardio Metabolic

Polypill for prevention of cardiovascular diseases with focus on non alcoholic steatohepatitis the PolyIran Liver trial

22 February 2024
Read more: Polypill for prevention of cardiovascular diseases with focus on non alcoholic steatohepatitis the PolyIran Liver trial
Top 10 Papers voted by ESC for 2023 in Cardio Metabolic

SGLT2 inhibitors in patients with heart failure: a comprehensive meta analysis of five randomised controlled trials

22 February 2024
Read more: SGLT2 inhibitors in patients with heart failure: a comprehensive meta analysis of five randomised controlled trials